Second-line chemotherapy in recurrent small cell lung cancer: Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen)

Lung Cancer

Volumn 48, Issue 2, 2005, Pages 251-261

  Sundstrøm, Stein ^a,b   Bremnes, Roy M ^c   Kaasa, Stein ^a,b   Aasebø, Ulf ^c   Aamdal, Steinar ^d  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Best supportive care; Crossover chemotherapy; Relapse; Small cell lung cancer

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LIFESPAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; SECOND LINE CANCER CHEMOTHERAPY; STATISTICAL ANALYSIS;

EID: 17044427576     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.10.016     Document Type: Article

References (32)

1. D.H. Johnson Management of small cell lung cancer. Current state of the art Chest 116 suppl 1999 525S 530S
2. R.L. Souhami, and K. Law Longevity in small cell lung cancer: a report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research Br J Cancer 61 1990 584 589
3. U. Lassen, K. Østerlind, and M. Hansen Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years. An analysis of 1714 consecutive patients J Clin Oncol 13 1995 1215 1220
4. C. Huisman, P.E. Postmus, and G. Giaccone Second-line chemotherapy and its evaluation in small cell lung cancer Cancer Treat Rev 25 1999 199 206
5. B.S. Glisson Recurrent small cell lung cancer: update Semin Oncol 1 2003 72 78
6. S. Sundstrøm, R.M. Bremnes, and S. Kaasa Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristin regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years follow-up J Clin Oncol. 20 2002 4665 4672
7. J.L. Pujol, L. Carestia, and J.P. Daures Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent Br J Cancer 83 2000 8 15
8. C. Mascaux, M. Paesmans, and T. Berghmans A systematic review of the role of etoposide and cisplatin in the chemotherapy in small cell lung cancer with methodology assessment and meta-analysis Lung Cancer 30 2000 23 36
9. R. Feld, W.K. Evans, and P. Coy Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung J Clin Oncol 5 1987 1401 1409
10. W.K. Evans, D. Osoba, and R. Feld Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small cell lung cancer J Clin Oncol 3 1985 67 71
11. J.H. Goldie, A.J. Coldman, and G.A. Gudauskas Rationale for the use of alternating non-cross-resistant chemotherapy Cancer Treat Rep 66 1982 439 449
12. M. Fukuoka, K. Furuse, and N. Saijo Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alteration of these regimens in small-cell lung cancer J Natl Cancer Inst 83 1991 855 861
13. B.J. Roth, D.H. Johnsen, and L.H. Einhorn Randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alteration of these two regimens in extensive small-cell lung cancer. A phase III trial of the Southeastern Cancer Study Group J Clin Oncol 10 1992 282 291
14. G.L. Wampler, W.J. Heim, and N.M. Ellison Comparison of cyclophosphamide, doxorubicin and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-Atlantic Oncology Program Study J Clin Oncol 9 1991 1438 1445
15. F.A. Shepherd, W.K. Evans, and R. MacCormick Cyclophosphamide, doxorubicin, and vincristin in etoposide and cisplatin-resistant small cell lung cancer Cancer Treat Rep 71 1987 941 944
16. R.M. Bremnes, S. Sundstrøm, and U. Aasebø The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up Lung Cancer 39 2003 303 313
17. A. Ardizzoni, H. Hansen, and P. Dombernowsky Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease J Clin Oncol 15 1997 2090 2096
18. E.I. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
19. D.R. Cox Regression models and life tables J R Stat Soc B 34 1972 187 202
20. P.E. Postmus, H.H. Berendsen, and Van Zandwijk Retreatment with the induction regimen in small cell lung cancer relapsing after initial response to short term chemotherapy Eur J Cancer Clin Oncol 23 1987 1409 1411
21. G. Giaccone Second-line chemotherapy in small cell lung cancer Lung Cancer 5 1989 207 213
22. K. Østerlind, and P.K. Anderson Prognostic factors in small cell lung cancer: multivariate model based on 728 patients with chemotherapy with or without radiation Cancer Res 46 1986 4189 4194
23. D. Yip, and P.G. Harper Predictive and prognostic factors in small cell lung cancer: current status Lung Cancer 28 2000 523 533
24. W. Schuette Chemotherapy as treatment of primary and recurrent small cell lung cancer Lung Cancer 33 2001 S99 S107
25. J.R. Eckardt Second-line treatment of small-cell lung cancer. The case for systematic chemotherapy Oncology 17 2003 181 191
26. N. Masuda, M. Fukuoka, and Y. Kusunoki CPT-11: a new derivative of camtothecin for the treatment of refractory or relapsed small-cell lung cancer J Clin Oncol 10 1992 1225 1229
27. N. Naka, M. Kawahara, and K. Okishio Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer Lung Cancer 37 2002 319 323
28. J.H. Schiller, K. Kim, and P. Hutson Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group trial J Clin Oncol. 14 1996 2345 2352
29. R. Perez-Soler, B.S. Glisson, and J.S. Lee Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with topoisomerase I poison Topotecan J Clin Oncol 14 1996 2785 2790
30. J. von Pawel, J.H. Schiller, and F.A. Shepard Topotecan versus cyclophosphamide, doxorubicin, and vincristin for the treatment of recurrent small-cell lung cancer J Clin Oncol 19 1999 1743 1749
31. H.J.M. Groen, E. Fokkema, and B. Biesma Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule J Clin Oncol 17 1999 927 932
32. C. Kosmas, N.B. Tsavaris, and N.A. Malamos Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small cell lung cancer J Clin Oncol 19 2001 119 126